Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David S Liao, MD, PhD
Retina-Vitreous Associates Medical Group
Principal Investigator - Rajesh C Rao, M.D.
University of Michigan Kellogg Eye Center
Principal Investigator - Theodore Leng, MD, FACS
Spencer Center for Vision Research at Stanford University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Retina Vitreous Associates Medical Group
Beverly Hills, California, United States
Recruiting - Spencer Center for Vision Research
Palo Alto, California, United States
Recruiting - University of Michigan Kellogg Eye Center
Ann Arbor, Michigan, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Apr 2022
- Primary completion
- 1 Dec 2026
- Completion
- 1 Dec 2026
- Last update posted
- 15 Oct 2025
- Registered enrollment
- 18
- Registry id
- NCT04627428
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.